{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["berberine", "neurological disorders"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35269418", "DateCompleted": {"Year": "2022", "Month": "04", "Day": "11"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "11"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "02", "Day": "24"}], "Language": ["eng"], "ELocationID": ["796", "10.3390/cells11050796"], "Journal": {"ISSN": "2073-4409", "JournalIssue": {"Volume": "11", "Issue": "5", "PubDate": {"Year": "2022", "Month": "Feb", "Day": "24"}}, "Title": "Cells", "ISOAbbreviation": "Cells"}, "ArticleTitle": "Therapeutic Efficacies of Berberine against Neurological Disorders: An Update of Pharmacological Effects and Mechanisms.", "Abstract": {"AbstractText": ["Neurological disorders are ranked as the leading cause of disability and the second leading cause of death worldwide, underscoring an urgent necessity to develop novel pharmacotherapies. Berberine (BBR) is a well-known phytochemical isolated from a number of medicinal herbs. BBR has attracted much interest for its broad range of pharmacological actions in treating and/or managing neurological disorders. The discoveries in basic and clinical studies of the effects of BBR on neurological disorders in the last decade have provided novel evidence to support the potential therapeutical efficacies of BBR in treating neurological diseases. In this review, we summarized the pharmacological properties and therapeutic applications of BBR against neurological disorders in the last decade. We also emphasized the major pathways modulated by BBR, which provides firm evidence for BBR as a promising drug candidate for neurological disorders."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Sciences, The Chinese University of Hong Kong, Hong Kong 852852, China."}], "LastName": "Shou", "ForeName": "Jia-Wen", "Initials": "JW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Sciences, The Chinese University of Hong Kong, Hong Kong 852852, China."}, {"Identifier": [], "Affiliation": "Li Dak Sum Yip Yio Chin R&D Centre for Chinese Medicine, The Chinese University of Hong Kong, Hong Kong 852852, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants and Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong 852852, China."}], "LastName": "Shaw", "ForeName": "Pang-Chui", "Initials": "PC"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cells", "NlmUniqueID": "101600052", "ISSNLinking": "2073-4409"}, "ChemicalList": [{"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Berberine"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Nervous System Diseases"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Stam C.J. Modern network science of neurological disorders. Nat. Rev. Neurosci. 2014;15:683\u2013695. doi: 10.1038/nrn3801.", "ArticleIdList": ["10.1038/nrn3801", "25186238"]}, {"Citation": "Global Burden of Disease Collaborators Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u2013480. doi: 10.1016/S1474-4422(18)30499-X.", "ArticleIdList": ["10.1016/S1474-4422(18)30499-X", "PMC6459001", "30879893"]}, {"Citation": "Feigin V.L., Vos T. Global Burden of Neurological Disorders: From Global Burden of Disease Estimates to Actions. Neuroepidemiology. 2019;52:1\u20132. doi: 10.1159/000495197.", "ArticleIdList": ["10.1159/000495197", "30472717"]}, {"Citation": "Gammon K. Neurodegenerative disease: Brain windfall. Nature. 2014;515:299\u2013300. doi: 10.1038/nj7526-299a.", "ArticleIdList": ["10.1038/nj7526-299a", "25396246"]}, {"Citation": "Hussain R., Zubair H., Pursell S., Shahab M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci. 2018;8:177. doi: 10.3390/brainsci8090177.", "ArticleIdList": ["10.3390/brainsci8090177", "PMC6162719", "30223579"]}, {"Citation": "Espay A.J., Aybek S., Carson A., Edwards M.J., Goldstein L.H., Hallett M., LaFaver K., LaFrance W.C., Jr., Lang A.E., Nicholson T., et al. Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurol. 2018;75:1132\u20131141. doi: 10.1001/jamaneurol.2018.1264.", "ArticleIdList": ["10.1001/jamaneurol.2018.1264", "PMC7293766", "29868890"]}, {"Citation": "Neag M.A., Mocan A., Echeverria J., Pop R.M., Bocsan C.I., Crisan G., Buzoianu A.D. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front. Pharmacol. 2018;9:557. doi: 10.3389/fphar.2018.00557.", "ArticleIdList": ["10.3389/fphar.2018.00557", "PMC6111450", "30186157"]}, {"Citation": "Jiang W., Li S., Li X. Therapeutic potential of berberine against neurodegenerative diseases. Sci. China Life Sci. 2015;58:564\u2013569. doi: 10.1007/s11427-015-4829-0.", "ArticleIdList": ["10.1007/s11427-015-4829-0", "PMC5823536", "25749423"]}, {"Citation": "Feng R., Zhao Z.X., Ma S.R., Guo F., Wang Y., Jiang J.D. Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration. Front. Pharmacol. 2018;9:214. doi: 10.3389/fphar.2018.00214.", "ArticleIdList": ["10.3389/fphar.2018.00214", "PMC5871679", "29618977"]}, {"Citation": "Feng R., Shou J.W., Zhao Z.X., He C.Y., Ma C., Huang M., Fu J., Tan X.S., Li X.Y., Wen B.Y., et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci. Rep. 2015;5:12155. doi: 10.1038/srep12155.", "ArticleIdList": ["10.1038/srep12155", "PMC4502414", "26174047"]}, {"Citation": "Tan X.S., Ma J.Y., Feng R., Ma C., Chen W.J., Sun Y.P., Fu J., Huang M., He C.Y., Shou J.W., et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS ONE. 2013;8:e77969. doi: 10.1371/journal.pone.0077969.", "ArticleIdList": ["10.1371/journal.pone.0077969", "PMC3815028", "24205048"]}, {"Citation": "Wang Y., Tong Q., Shou J.W., Zhao Z.X., Li X.Y., Zhang X.F., Ma S.R., He C.Y., Lin Y., Wen B.Y., et al. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics. 2017;7:2443\u20132451. doi: 10.7150/thno.18290.", "ArticleIdList": ["10.7150/thno.18290", "PMC5525748", "28744326"]}, {"Citation": "Zhao H.W., Shen Z., Zhou B., Lin X., Ye M. Studies on percutaneous absorption of ruyi jinhuang san patcher with radioisotope tracer. Zhongguo Zhong Yao Za Zhi. 1993;18:5.", "ArticleIdList": ["8216787"]}, {"Citation": "Chen W., Miao Y.Q., Fan D.J., Yang S.S., Lin X., Meng L.K., Tang X. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS Pharmscitech. 2011;12:705\u2013711. doi: 10.1208/s12249-011-9632-z.", "ArticleIdList": ["10.1208/s12249-011-9632-z", "PMC3134654", "21637946"]}, {"Citation": "Liu Y.T., Hao H.P., Xie H.G., Lai L., Wang Q., Liu C.X., Wang G.J. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab. Dispos. 2010;38:1779\u20131784. doi: 10.1124/dmd.110.033936.", "ArticleIdList": ["10.1124/dmd.110.033936", "20634337"]}, {"Citation": "Wang X., Wang R., Xing D., Su H., Ma C., Ding Y., Du L. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci. 2005;77:3058\u20133067. doi: 10.1016/j.lfs.2005.02.033.", "ArticleIdList": ["10.1016/j.lfs.2005.02.033", "15996686"]}, {"Citation": "Li Y., Ren G., Wang Y.X., Kong W.J., Yang P., Wang Y.M., Li Y.H., Yi H., Li Z.R., Song D.Q., et al. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J. Transl. Med. 2011;9:62. doi: 10.1186/1479-5876-9-62.", "ArticleIdList": ["10.1186/1479-5876-9-62", "PMC3103436", "21569619"]}, {"Citation": "Ma J.Y., Feng R., Tan X.S., Ma C., Shou J.W., Fu J., Huang M., He C.Y., Chen S.N., Zhao Z.X., et al. Excretion of berberine and its metabolites in oral administration in rats. J. Pharm. Sci. 2013;102:4181\u20134192. doi: 10.1002/jps.23718.", "ArticleIdList": ["10.1002/jps.23718", "24006193"]}, {"Citation": "Wang K., Chai L., Feng X., Liu Z., Liu H., Ding L., Qiu F. Metabolites identification of berberine in rats using ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 2017;139:73\u201386. doi: 10.1016/j.jpba.2017.02.038.", "ArticleIdList": ["10.1016/j.jpba.2017.02.038", "28279930"]}, {"Citation": "Hurley L.L., Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox. Res. 2013;23:131\u2013144. doi: 10.1007/s12640-012-9348-1.", "ArticleIdList": ["10.1007/s12640-012-9348-1", "PMC3751583", "22895696"]}, {"Citation": "Wong A.W.K., Lau S.C.L., Cella D., Lai J.S., Xie G., Chen L., Chan C.C.H., Heinemann A.W. Linking of the quality of life in neurological disorders (Neuro-QoL) to the international classification of functioning, disability and health. Qual. Life Res. 2017;26:2435\u20132448. doi: 10.1007/s11136-017-1590-9.", "ArticleIdList": ["10.1007/s11136-017-1590-9", "28477085"]}, {"Citation": "Dubois B., Hampel H., Feldman H.H., Scheltens P., Aisen P., Andrieu S., Bakardjian H., Benali H., Bertram L., Blennow K., et al. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323. doi: 10.1016/j.jalz.2016.02.002.", "ArticleIdList": ["10.1016/j.jalz.2016.02.002", "PMC6417794", "27012484"]}, {"Citation": "Sharma K. Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review) Mol. Med. Rep. 2019;20:1479\u20131487. doi: 10.3892/mmr.2019.10374.", "ArticleIdList": ["10.3892/mmr.2019.10374", "PMC6625431", "31257471"]}, {"Citation": "Singh M., Kaur M., Kukreja H., Chugh R., Silakari O., Singh D. Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. Eur. J. Med. Chem. 2013;70:165\u2013188. doi: 10.1016/j.ejmech.2013.09.050.", "ArticleIdList": ["10.1016/j.ejmech.2013.09.050", "24148993"]}, {"Citation": "Murphy M.P., LeVine H., 3rd Alzheimer\u2019s disease and the amyloid-beta peptide. J. Alzheimers Dis. 2010;19:311\u2013323. doi: 10.3233/JAD-2010-1221.", "ArticleIdList": ["10.3233/JAD-2010-1221", "PMC2813509", "20061647"]}, {"Citation": "Folch J., Petrov D., Ettcheto M., Abad S., Sanchez-Lopez E., Garcia M.L., Olloquequi J., Beas-Zarate C., Auladell C., Camins A. Current Research Therapeutic Strategies for Alzheimer\u2019s Disease Treatment. Neural Plast. 2016;2016:8501693. doi: 10.1155/2016/8501693.", "ArticleIdList": ["10.1155/2016/8501693", "PMC4735913", "26881137"]}, {"Citation": "Grossberg G.T. Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease: Getting on and staying on. Curr. Ther. Res. Clin. Exp. 2003;64:216\u2013235. doi: 10.1016/S0011-393X(03)00059-6.", "ArticleIdList": ["10.1016/S0011-393X(03)00059-6", "PMC4052996", "24944370"]}, {"Citation": "Colovic M.B., Krstic D.Z., Lazarevic-Pasti T.D., Bondzic A.M., Vasic V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol. 2013;11:315\u2013335. doi: 10.2174/1570159X11311030006.", "ArticleIdList": ["10.2174/1570159X11311030006", "PMC3648782", "24179466"]}, {"Citation": "De Oliveira J.S., Abdalla F.H., Dornelles G.L., Adefegha S.A., Palma T.V., Signor C., da Silva Bernardi J., Baldissarelli J., Lenz L.S., Magni L.P., et al. Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer\u2019s-like dementia: Involvement of acetylcholinesterase and cell death. Neurotoxicology. 2016;57:241\u2013250. doi: 10.1016/j.neuro.2016.10.008.", "ArticleIdList": ["10.1016/j.neuro.2016.10.008", "27746125"]}, {"Citation": "Hussien H.M., Abd-Elmegied A., Ghareeb D.A., Hafez H.S., Ahmed H.E.A., El-Moneam N.A. Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer\u2019s-like disease in rats. Food Chem. Toxicol. 2018;111:432\u2013444. doi: 10.1016/j.fct.2017.11.025.", "ArticleIdList": ["10.1016/j.fct.2017.11.025", "29170048"]}, {"Citation": "Ji H.F., Shen L. Molecular basis of inhibitory activities of berberine against pathogenic enzymes in Alzheimer\u2019s disease. Sci. World J. 2012;2012:823201. doi: 10.1100/2012/823201.", "ArticleIdList": ["10.1100/2012/823201", "PMC3259606", "22262957"]}, {"Citation": "Ling Y., Morgan K., Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: Relevance to Alzheimer\u2019s disease. Int. J. Biochem. Cell Biol. 2003;35:1505\u20131535. doi: 10.1016/S1357-2725(03)00133-X.", "ArticleIdList": ["10.1016/S1357-2725(03)00133-X", "12824062"]}, {"Citation": "O\u2019Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu. Rev. Neurosci. 2011;34:185\u2013204. doi: 10.1146/annurev-neuro-061010-113613.", "ArticleIdList": ["10.1146/annurev-neuro-061010-113613", "PMC3174086", "21456963"]}, {"Citation": "Congdon E.E., Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018;14:399\u2013415. doi: 10.1038/s41582-018-0013-z.", "ArticleIdList": ["10.1038/s41582-018-0013-z", "PMC6463489", "29895964"]}, {"Citation": "Durairajan S.S., Liu L.F., Lu J.H., Chen L.L., Yuan Q., Chung S.K., Huang L., Li X.S., Huang J.D., Li M. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer\u2019s disease transgenic mouse model. Neurobiol. Aging. 2012;33:2903\u20132919. doi: 10.1016/j.neurobiolaging.2012.02.016.", "ArticleIdList": ["10.1016/j.neurobiolaging.2012.02.016", "22459600"]}, {"Citation": "Liang Y., Ye C., Chen Y., Chen Y., Diao S., Huang M. Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer\u2019s Disease via Regulation of beta-Amyloid Production and Endoplasmic Reticulum Stress. ACS Chem. Neurosci. 2021;12:1894\u20131904. doi: 10.1021/acschemneuro.0c00808.", "ArticleIdList": ["10.1021/acschemneuro.0c00808", "33983710"]}, {"Citation": "Cai Z., Wang C., He W., Chen Y. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting beta/gamma-Secretases Activity and Enhancing alpha-Secretases. Curr. Alzheimer Res. 2018;15:1045\u20131052. doi: 10.2174/1567205015666180702105740.", "ArticleIdList": ["10.2174/1567205015666180702105740", "29962345"]}, {"Citation": "Huang M., Jiang X., Liang Y., Liu Q., Chen S., Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of beta-amyloid in APP/tau/PS1 mouse model of Alzheimer\u2019s disease. Exp. Gerontol. 2017;91:25\u201333. doi: 10.1016/j.exger.2017.02.004.", "ArticleIdList": ["10.1016/j.exger.2017.02.004", "28223223"]}, {"Citation": "Wu Y., Chen Q., Wen B., Wu N., He B., Chen J. Berberine Reduces Abeta42 Deposition and Tau Hyperphosphorylation via Ameliorating Endoplasmic Reticulum Stress. Front. Pharmacol. 2021;12:640758. doi: 10.3389/fphar.2021.640758.", "ArticleIdList": ["10.3389/fphar.2021.640758", "PMC8327086", "34349640"]}, {"Citation": "Wang Y.Y., Yan Q., Huang Z.T., Zou Q., Li J., Yuan M.H., Wu L.Q., Cai Z.Y. Ameliorating Ribosylation-Induced Amyloid-beta Pathology by Berberine via Inhibiting mTOR/p70S6K Signaling. J. Alzheimers Dis. 2021;79:833\u2013844. doi: 10.3233/JAD-200995.", "ArticleIdList": ["10.3233/JAD-200995", "33361598"]}, {"Citation": "Reiss A.B., Arain H.A., Stecker M.M., Siegart N.M., Kasselman L.J. Amyloid toxicity in Alzheimer\u2019s disease. Rev. Neurosci. 2018;29:613\u2013627. doi: 10.1515/revneuro-2017-0063.", "ArticleIdList": ["10.1515/revneuro-2017-0063", "29447116"]}, {"Citation": "Haghani M., Shabani M., Tondar M. The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Abeta neurotoxicity. Eur. J. Pharmacol. 2015;758:82\u201388. doi: 10.1016/j.ejphar.2015.03.016.", "ArticleIdList": ["10.1016/j.ejphar.2015.03.016", "25861937"]}, {"Citation": "He W., Wang C., Chen Y., He Y., Cai Z. Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-kappaB signaling, oxidative stress and neuroinflammation. Pharmacol. Rep. 2017;69:1341\u20131348. doi: 10.1016/j.pharep.2017.06.006.", "ArticleIdList": ["10.1016/j.pharep.2017.06.006", "29132092"]}, {"Citation": "Heurtaux T., Michelucci A., Losciuto S., Gallotti C., Felten P., Dorban G., Grandbarbe L., Morga E., Heuschling P. Microglial activation depends on beta-amyloid conformation: Role of the formylpeptide receptor 2. J. Neurochem. 2010;114:576\u2013586. doi: 10.1111/j.1471-4159.2010.06783.x.", "ArticleIdList": ["10.1111/j.1471-4159.2010.06783.x", "20456016"]}, {"Citation": "Guo Q., Wang C., Xue X., Hu B., Bao H. SOCS1 Mediates Berberine-Induced Amelioration of Microglial Activated States in N9 Microglia Exposed to beta Amyloid. Biomed. Res. Int. 2021;2021:9311855. doi: 10.1155/2021/9311855.", "ArticleIdList": ["10.1155/2021/9311855", "PMC8589517", "34778460"]}, {"Citation": "Chen Y., Chen Y., Liang Y., Chen H., Ji X., Huang M. Berberine mitigates cognitive decline in an Alzheimer\u2019s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed. Pharmacother. 2020;121:109670. doi: 10.1016/j.biopha.2019.109670.", "ArticleIdList": ["10.1016/j.biopha.2019.109670", "31810131"]}, {"Citation": "Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson\u2019s disease. Neuron. 2010;66:646\u2013661. doi: 10.1016/j.neuron.2010.04.034.", "ArticleIdList": ["10.1016/j.neuron.2010.04.034", "PMC2917798", "20547124"]}, {"Citation": "Kim M., Cho K.H., Shin M.S., Lee J.M., Cho H.S., Kim C.J., Shin D.H., Yang H.J. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson\u2019s disease. Int. J. Mol. Med. 2014;33:870\u2013878. doi: 10.3892/ijmm.2014.1656.", "ArticleIdList": ["10.3892/ijmm.2014.1656", "24535622"]}, {"Citation": "Deng H., Ma Z. Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct. 2021;12:8366\u20138375. doi: 10.1039/D1FO01360B.", "ArticleIdList": ["10.1039/D1FO01360B", "34342315"]}, {"Citation": "Huang S., Liu H., Lin Y., Liu M., Li Y., Mao H., Zhang Z., Zhang Y., Ye P., Ding L., et al. Berberine Protects Against NLRP3 Inflammasome via Ameliorating Autophagic Impairment in MPTP-Induced Parkinson\u2019s Disease Model. Front. Pharmacol. 2020;11:618787. doi: 10.3389/fphar.2020.618787.", "ArticleIdList": ["10.3389/fphar.2020.618787", "PMC7872967", "33584302"]}, {"Citation": "Wang Y., Tong Q., Ma S.R., Zhao Z.X., Pan L.B., Cong L., Han P., Peng R., Yu H., Lin Y., et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson\u2019s disease by regulating gut microbiota. Signal. Transduct. Target. Ther. 2021;6:77. doi: 10.1038/s41392-020-00456-5.", "ArticleIdList": ["10.1038/s41392-020-00456-5", "PMC7902645", "33623004"]}, {"Citation": "Bae J., Lee D., Kim Y.K., Gil M., Lee J.Y., Lee K.J. Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol. Cells. 2013;35:151\u2013157. doi: 10.1007/s10059-013-2298-5.", "ArticleIdList": ["10.1007/s10059-013-2298-5", "PMC3887902", "23329300"]}, {"Citation": "Zhang C., Li C., Chen S., Li Z., Jia X., Wang K., Bao J., Liang Y., Wang X., Chen M., et al. Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways. Redox Biol. 2017;11:1\u201311. doi: 10.1016/j.redox.2016.10.019.", "ArticleIdList": ["10.1016/j.redox.2016.10.019", "PMC5107737", "27835779"]}, {"Citation": "Inden M., Kitamura Y., Abe M., Tamaki A., Takata K., Taniguchi T. Parkinsonian rotenone mouse model: Reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol. Pharm. Bull. 2011;34:92\u201396. doi: 10.1248/bpb.34.92.", "ArticleIdList": ["10.1248/bpb.34.92", "21212524"]}, {"Citation": "Kysenius K., Brunello C.A., Huttunen H.J. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS ONE. 2014;9:e107129. doi: 10.1371/journal.pone.0107129.", "ArticleIdList": ["10.1371/journal.pone.0107129", "PMC4156429", "25192195"]}, {"Citation": "Deng H., Jia Y., Pan D., Ma Z. Berberine alleviates rotenone-induced cytotoxicity by antioxidation and activation of PI3K/Akt signaling pathway in SH-SY5Y cells. Neuroreport. 2020;31:41\u201347. doi: 10.1097/WNR.0000000000001365.", "ArticleIdList": ["10.1097/WNR.0000000000001365", "31688419"]}, {"Citation": "Chugh C. Acute Ischemic Stroke: Management Approach. Indian J. Crit. Care Med. 2019;23:S140\u2013S146. doi: 10.5005/jp-journals-10071-23192.", "ArticleIdList": ["10.5005/jp-journals-10071-23192", "PMC6707502", "31485123"]}, {"Citation": "Kuriakose D., Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int. J. Mol. Sci. 2020;21:7609. doi: 10.3390/ijms21207609.", "ArticleIdList": ["10.3390/ijms21207609", "PMC7589849", "33076218"]}, {"Citation": "Kinlay S. Changes in stroke epidemiology, prevention, and treatment. Circulation. 2011;124:e494\u2013e496. doi: 10.1161/CIRCULATIONAHA.111.069633.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.111.069633", "PMC4501778", "22064961"]}, {"Citation": "Wang X., Zhang Y., Yang Y., Wu X., Fan H., Qiao Y. Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies. Sci. Rep. 2017;7:44040. doi: 10.1038/srep44040.", "ArticleIdList": ["10.1038/srep44040", "PMC5343495", "28276481"]}, {"Citation": "Liu F., McCullough L.D. Middle cerebral artery occlusion model in rodents: Methods and potential pitfalls. J. Biomed. Biotechnol. 2011;2011:464701. doi: 10.1155/2011/464701.", "ArticleIdList": ["10.1155/2011/464701", "PMC3035178", "21331357"]}, {"Citation": "Manzanero S., Santro T., Arumugam T.V. Neuronal oxidative stress in acute ischemic stroke: Sources and contribution to cell injury. Neurochem. Int. 2013;62:712\u2013718. doi: 10.1016/j.neuint.2012.11.009.", "ArticleIdList": ["10.1016/j.neuint.2012.11.009", "23201332"]}, {"Citation": "Majid A. Neuroprotection in stroke: Past, present, and future. ISRN Neurol. 2014;2014:515716. doi: 10.1155/2014/515716.", "ArticleIdList": ["10.1155/2014/515716", "PMC3918861", "24579051"]}, {"Citation": "Zhu J.R., Lu H.D., Guo C., Fang W.R., Zhao H.D., Zhou J.S., Wang F., Zhao Y.L., Li Y.M., Zhang Y.D., et al. Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF-kappaB nuclear translocation. Acta Pharmacol. Sin. 2018;39:1706\u20131715. doi: 10.1038/s41401-018-0160-1.", "ArticleIdList": ["10.1038/s41401-018-0160-1", "PMC6289370", "30266998"]}, {"Citation": "Ramiro L., Simats A., Garcia-Berrocoso T., Montaner J. Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Ther. Adv. Neurol. Disord. 2018;11:1756286418789340. doi: 10.1177/1756286418789340.", "ArticleIdList": ["10.1177/1756286418789340", "PMC6080077", "30093920"]}, {"Citation": "Yang C., Hawkins K.E., Dore S., Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am. J. Physiol. Cell Physiol. 2019;316:C135\u2013C153. doi: 10.1152/ajpcell.00136.2018.", "ArticleIdList": ["10.1152/ajpcell.00136.2018", "PMC6397344", "30379577"]}, {"Citation": "Zhang Q., Fu X., Wang J., Yang M., Kong L. Treatment Effects of Ischemic Stroke by Berberine, Baicalin, and Jasminoidin from Huang-Lian-Jie-Du-Decoction (HLJDD) Explored by an Integrated Metabolomics Approach. Oxid. Med. Cell. Longev. 2017;2017:9848594. doi: 10.1155/2017/9848594.", "ArticleIdList": ["10.1155/2017/9848594", "PMC5574319", "28894512"]}, {"Citation": "Pradeep H., Diya J.B., Shashikumar S., Rajanikant G.K. Oxidative stress\u2014Assassin behind the ischemic stroke. Folia Neuropathol. 2012;50:219\u2013230. doi: 10.5114/fn.2012.30522.", "ArticleIdList": ["10.5114/fn.2012.30522", "23023336"]}, {"Citation": "Chen W., Wei S., Yu Y., Xue H., Yao F., Zhang M., Xiao J., Hatch G.M., Chen L. Pretreatment of rats with increased bioavailable berberine attenuates cerebral ischemia-reperfusion injury via down regulation of adenosine-5\u2032 monophosphate kinase activity. Eur. J. Pharmacol. 2016;779:80\u201390. doi: 10.1016/j.ejphar.2016.03.015.", "ArticleIdList": ["10.1016/j.ejphar.2016.03.015", "26957053"]}, {"Citation": "Hu J., Chai Y., Wang Y., Kheir M.M., Li H., Yuan Z., Wan H., Xing D., Lei F., Du L. PI3K p55gamma promoter activity enhancement is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion. Eur. J. Pharmacol. 2012;674:132\u2013142. doi: 10.1016/j.ejphar.2011.11.014.", "ArticleIdList": ["10.1016/j.ejphar.2011.11.014", "22119079"]}, {"Citation": "Simoes Pires E.N., Frozza R.L., Hoppe J.B., Menezes Bde M., Salbego C.G. Berberine was neuroprotective against an in vitro model of brain ischemia: Survival and apoptosis pathways involved. Brain Res. 2014;1557:26\u201333. doi: 10.1016/j.brainres.2014.02.021.", "ArticleIdList": ["10.1016/j.brainres.2014.02.021", "24560603"]}, {"Citation": "Zhang Q., Qian Z., Pan L., Li H., Zhu H. Hypoxia-inducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia/ischemia. Acta Physiol. Hung. 2012;99:311\u2013323. doi: 10.1556/APhysiol.99.2012.3.8.", "ArticleIdList": ["10.1556/APhysiol.99.2012.3.8", "22982719"]}, {"Citation": "Yang J., Yan H., Li S., Zhang M. Berberine Ameliorates MCAO Induced Cerebral Ischemia/Reperfusion Injury via Activation of the BDNF-TrkB-PI3K/Akt Signaling Pathway. Neurochem. Res. 2018;43:702\u2013710. doi: 10.1007/s11064-018-2472-4.", "ArticleIdList": ["10.1007/s11064-018-2472-4", "29357017"]}, {"Citation": "Chai Y.S., Yuan Z.Y., Lei F., Wang Y.G., Hu J., Du F., Lu X., Jiang J.F., Xing D.M., Du L.J. Inhibition of retinoblastoma mRNA degradation through Poly (A) involved in the neuroprotective effect of berberine against cerebral ischemia. PLoS ONE. 2014;9:e90850. doi: 10.1371/journal.pone.0090850.", "ArticleIdList": ["10.1371/journal.pone.0090850", "PMC3946351", "24603897"]}, {"Citation": "Maleki S.N., Aboutaleb N., Souri F. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting inflammatory cytokines. J. Chem. Neuroanat. 2018;87:54\u201359. doi: 10.1016/j.jchemneu.2017.04.008.", "ArticleIdList": ["10.1016/j.jchemneu.2017.04.008", "PMC5812778", "28495517"]}, {"Citation": "Zhang X., Zhang X., Wang C., Li Y., Dong L., Cui L., Wang L., Liu Z., Qiao H., Zhu C., et al. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: Up-regulated pAkt, pGSK and pCREB, down-regulated NF-kappaB expression, ameliorated BBB permeability. Brain Res. 2012;1459:61\u201370. doi: 10.1016/j.brainres.2012.03.065.", "ArticleIdList": ["10.1016/j.brainres.2012.03.065", "22560097"]}, {"Citation": "Shou J.W., Li X.X., Tang Y.S., Lim-Ho Kong B., Wu H.Y., Xiao M.J., Cheung C.K., Shaw P.C. Novel mechanistic insight on the neuroprotective effect of berberine: The role of PPARdelta for antioxidant action. Free Radic. Biol. Med. 2022;181:62\u201371. doi: 10.1016/j.freeradbiomed.2022.01.022.", "ArticleIdList": ["10.1016/j.freeradbiomed.2022.01.022", "35093536"]}, {"Citation": "Zhu J., Cao D., Guo C., Liu M., Tao Y., Zhou J., Wang F., Zhao Y., Wei J., Zhang Y., et al. Berberine Facilitates Angiogenesis Against Ischemic Stroke through Modulating Microglial Polarization via AMPK Signaling. Cell. Mol. Neurobiol. 2019;39:751\u2013768. doi: 10.1007/s10571-019-00675-7.", "ArticleIdList": ["10.1007/s10571-019-00675-7", "31020571"]}, {"Citation": "McColgan P., Tabrizi S.J. Huntington\u2019s disease: A clinical review. Eur. J. Neurol. 2018;25:24\u201334. doi: 10.1111/ene.13413.", "ArticleIdList": ["10.1111/ene.13413", "28817209"]}, {"Citation": "Ross C.A., Tabrizi S.J. Huntington\u2019s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398. doi: 10.1016/S1474-4422(10)70245-3.", "ArticleIdList": ["10.1016/S1474-4422(10)70245-3", "21163446"]}, {"Citation": "Jiang W., Wei W., Gaertig M.A., Li S., Li X.J. Therapeutic Effect of Berberine on Huntington\u2019s Disease Transgenic Mouse Model. PLoS ONE. 2015;10:e0134142. doi: 10.1371/journal.pone.0134142.", "ArticleIdList": ["10.1371/journal.pone.0134142", "PMC4520448", "26225560"]}, {"Citation": "Wimo A., Guerchet M., Ali G.C., Wu Y.T., Prina A.M., Winblad B., Jonsson L., Liu Z., Prince M. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1\u20137. doi: 10.1016/j.jalz.2016.07.150.", "ArticleIdList": ["10.1016/j.jalz.2016.07.150", "PMC5232417", "27583652"]}, {"Citation": "Wahl D., Solon-Biet S.M., Cogger V.C., Fontana L., Simpson S.J., Le Couteur D.G., Ribeiro R.V. Aging, lifestyle and dementia. Neurobiol. Dis. 2019;130:104481. doi: 10.1016/j.nbd.2019.104481.", "ArticleIdList": ["10.1016/j.nbd.2019.104481", "31136814"]}, {"Citation": "Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844\u2013866. doi: 10.1016/j.neuron.2013.10.008.", "ArticleIdList": ["10.1016/j.neuron.2013.10.008", "PMC3842016", "24267647"]}, {"Citation": "Aski M.L., Rezvani M.E., Khaksari M., Hafizi Z., Pirmoradi Z., Niknazar S., Mehrjerdi F.Z. Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. Iran. J. Basic Med. Sci. 2018;21:53\u201358. doi: 10.22038/IJBMS.2017.23195.5865.", "ArticleIdList": ["10.22038/IJBMS.2017.23195.5865", "PMC5776437", "29372037"]}, {"Citation": "Yin S., Bai W., Li P., Jian X., Shan T., Tang Z., Jing X., Ping S., Li Q., Miao Z., et al. Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats. Clin. Exp. Hypertens. 2019;41:708\u2013716. doi: 10.1080/10641963.2018.1545846.", "ArticleIdList": ["10.1080/10641963.2018.1545846", "30472896"]}, {"Citation": "Sadraie S., Kiasalari Z., Razavian M., Azimi S., Sedighnejad L., Afshin-Majd S., Baluchnejadmojarad T., Roghani M. Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: Insights into underlying molecular mechanisms. Metab. Brain Dis. 2019;34:245\u2013255. doi: 10.1007/s11011-018-0349-5.", "ArticleIdList": ["10.1007/s11011-018-0349-5", "30456649"]}, {"Citation": "Shaker F.H., El-Derany M.O., Wahdan S.A., El-Demerdash E., El-Mesallamy H.O. Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats. Life Sci. 2021;269:119078. doi: 10.1016/j.lfs.2021.119078.", "ArticleIdList": ["10.1016/j.lfs.2021.119078", "33460662"]}, {"Citation": "Zhan P.Y., Peng C.X., Zhang L.H. Berberine rescues D-galactose-induced synaptic/memory impairment by regulating the levels of Arc. Pharmacol. Biochem. Behav. 2014;117:47\u201351. doi: 10.1016/j.pbb.2013.12.006.", "ArticleIdList": ["10.1016/j.pbb.2013.12.006", "24342459"]}, {"Citation": "Krystal J.H., State M.W. Psychiatric disorders: Diagnosis to therapy. Cell. 2014;157:201\u2013214. doi: 10.1016/j.cell.2014.02.042.", "ArticleIdList": ["10.1016/j.cell.2014.02.042", "PMC4104191", "24679536"]}, {"Citation": "Owen M.J. New approaches to psychiatric diagnostic classification. Neuron. 2014;84:564\u2013571. doi: 10.1016/j.neuron.2014.10.028.", "ArticleIdList": ["10.1016/j.neuron.2014.10.028", "25442935"]}, {"Citation": "Cabral P., Meyer H.B., Ames D. Effectiveness of yoga therapy as a complementary treatment for major psychiatric disorders: A meta-analysis. Prim. Care Companion CNS Disord. 2011;13:26290. doi: 10.4088/PCC.10r01068.", "ArticleIdList": ["10.4088/PCC.10r01068", "PMC3219516", "22132353"]}, {"Citation": "Hesdorffer D.C., Ishihara L., Mynepalli L., Webb D.J., Weil J., Hauser W.A. Epilepsy, suicidality, and psychiatric disorders: A bidirectional association. Ann. Neurol. 2012;72:184\u2013191. doi: 10.1002/ana.23601.", "ArticleIdList": ["10.1002/ana.23601", "22887468"]}, {"Citation": "LaFrance W.C., Jr., Kanner A.M., Hermann B. Psychiatric comorbidities in epilepsy. Int. Rev. Neurobiol. 2008;83:347\u2013383. doi: 10.1016/S0074-7742(08)00020-2.", "ArticleIdList": ["10.1016/S0074-7742(08)00020-2", "18929092"]}, {"Citation": "Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. Lancet. 2016;388:86\u201397. doi: 10.1016/S0140-6736(15)01121-6.", "ArticleIdList": ["10.1016/S0140-6736(15)01121-6", "PMC4940219", "26777917"]}, {"Citation": "Ghotbi Ravandi S., Shabani M., Bashiri H., Saeedi Goraghani M., Khodamoradi M., Nozari M. Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. Neurosci. Lett. 2019;706:151\u2013157. doi: 10.1016/j.neulet.2019.05.029.", "ArticleIdList": ["10.1016/j.neulet.2019.05.029", "31103726"]}, {"Citation": "Tiller J.W. Depression and anxiety. Med. J. Aust. 2013;199:S28\u2013S31. doi: 10.5694/mja12.10628.", "ArticleIdList": ["10.5694/mja12.10628", "25370281"]}, {"Citation": "Penninx B.W., Pine D.S., Holmes E.A., Reif A. Anxiety disorders. Lancet. 2021;397:914\u2013927. doi: 10.1016/S0140-6736(21)00359-7.", "ArticleIdList": ["10.1016/S0140-6736(21)00359-7", "33581801"]}, {"Citation": "Lee B., Sur B., Yeom M., Shim I., Lee H., Hahm D.H. Effect of berberine on depression- and anxiety-like behaviors and activation of the noradrenergic system induced by development of morphine dependence in rats. Korean J. Physiol. Pharmacol. 2012;16:379\u2013386. doi: 10.4196/kjpp.2012.16.6.379.", "ArticleIdList": ["10.4196/kjpp.2012.16.6.379", "PMC3526741", "23269899"]}, {"Citation": "Rezaeian L., Kalalian-Moghaddam H., Mohseni F., Khaksari M., Rafaiee R. Effects of berberine hydrochloride on methamphetamine-induced anxiety behaviors and relapse in rats. Iran. J. Basic Med. Sci. 2020;23:1480\u20131488. doi: 10.22038/ijbms.2020.47285.10884.", "ArticleIdList": ["10.22038/ijbms.2020.47285.10884", "PMC7671426", "33235706"]}, {"Citation": "Alavijeh M.M., Vaezi G., Khaksari M., Hojati V. Berberine hydrochloride attenuates voluntary methamphetamine consumption and anxiety-like behaviors via modulation of oxytocin receptors in methamphetamine addicted rats. Physiol. Behav. 2019;206:157\u2013165. doi: 10.1016/j.physbeh.2019.03.024.", "ArticleIdList": ["10.1016/j.physbeh.2019.03.024", "30922821"]}, {"Citation": "Muhlethaler M., Charpak S., Dreifuss J.J. Contrasting effects of neurohypophysial peptides on pyramidal and non-pyramidal neurones in the rat hippocampus. Brain Res. 1984;308:97\u2013107. doi: 10.1016/0006-8993(84)90921-1.", "ArticleIdList": ["10.1016/0006-8993(84)90921-1", "6478205"]}, {"Citation": "Mulhall S., Andel R., Anstey K.J. Variation in symptoms of depression and anxiety in midlife women by menopausal status. Maturitas. 2018;108:7\u201312. doi: 10.1016/j.maturitas.2017.11.005.", "ArticleIdList": ["10.1016/j.maturitas.2017.11.005", "29290217"]}, {"Citation": "Cyranowski J.M. Practice considerations for behavioral therapies for depression and anxiety in midlife women. Menopause. 2022;29:236\u2013238. doi: 10.1097/GME.0000000000001908.", "ArticleIdList": ["10.1097/GME.0000000000001908", "35013055"]}, {"Citation": "Cohen L.S., Soares C.N., Vitonis A.F., Otto M.W., Harlow B.L. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch. Gen. Psychiatry. 2006;63:385\u2013390. doi: 10.1001/archpsyc.63.4.385.", "ArticleIdList": ["10.1001/archpsyc.63.4.385", "16585467"]}, {"Citation": "Fan J., Li B., Ge T., Zhang Z., Lv J., Zhao J., Wang P., Liu W., Wang X., Mlyniec K., et al. Berberine produces antidepressant-like effects in ovariectomized mice. Sci. Rep. 2017;7:1310. doi: 10.1038/s41598-017-01035-5.", "ArticleIdList": ["10.1038/s41598-017-01035-5", "PMC5431015", "28465511"]}, {"Citation": "Fang Y., Zhang J., Zhu S., He M., Ma S., Jia Q., Sun Q., Song L., Wang Y., Duan L. Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota. Pharmacol. Res. 2021;165:105439. doi: 10.1016/j.phrs.2021.105439.", "ArticleIdList": ["10.1016/j.phrs.2021.105439", "33493658"]}, {"Citation": "Shneker B.F., Fountain N.B. Epilepsy. Dis. Mon. 2003;49:426\u2013478. doi: 10.1016/S0011-5029(03)00065-8.", "ArticleIdList": ["10.1016/S0011-5029(03)00065-8", "12838266"]}, {"Citation": "Schubert J., Siekierska A., Langlois M., May P., Huneau C., Becker F., Muhle H., Suls A., Lemke J.R., de Kovel C.G., et al. Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. Nat. Genet. 2014;46:1327\u20131332. doi: 10.1038/ng.3130.", "ArticleIdList": ["10.1038/ng.3130", "25362483"]}, {"Citation": "Zheng Y.M., Chen B., Jiang J.D., Zhang J.P. Syntaxin 1B Mediates Berberine\u2019s Roles in Epilepsy-Like Behavior in a Pentylenetetrazole-Induced Seizure Zebrafish Model. Front. Mol. Neurosci. 2018;11:378. doi: 10.3389/fnmol.2018.00378.", "ArticleIdList": ["10.3389/fnmol.2018.00378", "PMC6275243", "30534049"]}, {"Citation": "Ambrogini P., Torquato P., Bartolini D., Albertini M.C., Lattanzi D., Di Palma M., Marinelli R., Betti M., Minelli A., Cuppini R., et al. Excitotoxicity, neuroinflammation and oxidant stress as molecular bases of epileptogenesis and epilepsy-derived neurodegeneration: The role of vitamin E. Biochim. Biophys. Acta Mol. Basis Dis. 2019;1865:1098\u20131112. doi: 10.1016/j.bbadis.2019.01.026.", "ArticleIdList": ["10.1016/j.bbadis.2019.01.026", "30703511"]}, {"Citation": "Sedaghat R., Taab Y., Kiasalari Z., Afshin-Majd S., Baluchnejadmojarad T., Roghani M. Berberine ameliorates intrahippocampal kainate-induced status epilepticus and consequent epileptogenic process in the rat: Underlying mechanisms. Biomed. Pharmacother. 2017;87:200\u2013208. doi: 10.1016/j.biopha.2016.12.109.", "ArticleIdList": ["10.1016/j.biopha.2016.12.109", "28061403"]}, {"Citation": "Gao F., Gao Y., Liu Y.F., Wang L., Li Y.J. Berberine exerts an anticonvulsant effect and ameliorates memory impairment and oxidative stress in a pilocarpine-induced epilepsy model in the rat. Neuropsychiatr. Dis. Treat. 2014;10:2139\u20132145. doi: 10.2147/NDT.S73210.", "ArticleIdList": ["10.2147/NDT.S73210", "PMC4235502", "25419137"]}, {"Citation": "Mojarad T.B., Roghani M. The Anticonvulsant and Antioxidant Effects of Berberine in Kainate-induced Temporal Lobe Epilepsy in Rats. Basic Clin. Neurosci. 2014;5:124\u2013130.", "ArticleIdList": ["PMC4202588", "25337370"]}, {"Citation": "Guna V., Saha L., Bhatia A., Banerjee D., Chakrabarti A. Anti-Oxidant and Anti-Apoptotic Effects of Berberine in Pentylenetetrazole-Induced Kindling Model in Rat. J. Epilepsy Res. 2018;8:66\u201373. doi: 10.14581/jer.18011.", "ArticleIdList": ["10.14581/jer.18011", "PMC6374532", "30809499"]}, {"Citation": "Zhang B., Wang L., Ji X., Zhang S., Sik A., Liu K., Jin M. Anti-Inflammation Associated Protective Mechanism of Berberine and its Derivatives on Attenuating Pentylenetetrazole-Induced Seizures in Zebrafish. J. Neuroimmune Pharmacol. 2020;15:309\u2013325. doi: 10.1007/s11481-019-09902-w.", "ArticleIdList": ["10.1007/s11481-019-09902-w", "31909440"]}, {"Citation": "Galgano M., Toshkezi G., Qiu X., Russell T., Chin L., Zhao L.R. Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors. Cell Transplant. 2017;26:1118\u20131130. doi: 10.1177/0963689717714102.", "ArticleIdList": ["10.1177/0963689717714102", "PMC5657730", "28933211"]}, {"Citation": "Werner C., Engelhard K. Pathophysiology of traumatic brain injury. Br. J. Anaesth. 2007;99:4\u20139. doi: 10.1093/bja/aem131.", "ArticleIdList": ["10.1093/bja/aem131", "17573392"]}, {"Citation": "Huang S.X., Qiu G., Cheng F.R., Pei Z., Yang Z., Deng X.H., Zhu J.H., Chen L., Chen C.C., Lin W.F., et al. Berberine Protects Secondary Injury in Mice with Traumatic Brain Injury Through Anti-oxidative and Anti-inflammatory Modulation. Neurochem. Res. 2018;43:1814\u20131825. doi: 10.1007/s11064-018-2597-5.", "ArticleIdList": ["10.1007/s11064-018-2597-5", "30027364"]}, {"Citation": "Chen C.C., Hung T.H., Lee C.Y., Wang L.F., Wu C.H., Ke C.H., Chen S.F. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS ONE. 2014;9:e115694. doi: 10.1371/journal.pone.0115694.", "ArticleIdList": ["10.1371/journal.pone.0115694", "PMC4278716", "25546475"]}, {"Citation": "Barnholtz-Sloan J.S., Ostrom Q.T., Cote D. Epidemiology of Brain Tumors. Neurol. Clin. 2018;36:395\u2013419. doi: 10.1016/j.ncl.2018.04.001.", "ArticleIdList": ["10.1016/j.ncl.2018.04.001", "30072062"]}, {"Citation": "Lapointe S., Perry A., Butowski N.A. Primary brain tumours in adults. Lancet. 2018;392:432\u2013446. doi: 10.1016/S0140-6736(18)30990-5.", "ArticleIdList": ["10.1016/S0140-6736(18)30990-5", "30060998"]}, {"Citation": "Wang J., Qi Q., Feng Z., Zhang X., Huang B., Chen A., Prestegarden L., Li X., Wang J. Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget. 2016;7:66944\u201366958. doi: 10.18632/oncotarget.11396.", "ArticleIdList": ["10.18632/oncotarget.11396", "PMC5341849", "27557493"]}, {"Citation": "Sun Y., Yu J., Liu X., Zhang C., Cao J., Li G., Liu X., Chen Y., Huang H. Oncosis-like cell death is induced by berberine through ERK1/2-mediated impairment of mitochondrial aerobic respiration in gliomas. Biomed. Pharmacother. 2018;102:699\u2013710. doi: 10.1016/j.biopha.2018.03.132.", "ArticleIdList": ["10.1016/j.biopha.2018.03.132", "29604589"]}, {"Citation": "Weerasinghe P., Buja L.M. Oncosis: An important non-apoptotic mode of cell death. Exp. Mol. Pathol. 2012;93:302\u2013308. doi: 10.1016/j.yexmp.2012.09.018.", "ArticleIdList": ["10.1016/j.yexmp.2012.09.018", "23036471"]}, {"Citation": "Liu Q., Xu X., Zhao M., Wei Z., Li X., Zhang X., Liu Z., Gong Y., Shao C. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol. Cancer Ther. 2015;14:355\u2013363. doi: 10.1158/1535-7163.MCT-14-0634.", "ArticleIdList": ["10.1158/1535-7163.MCT-14-0634", "25504754"]}, {"Citation": "Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007;8:610\u2013622. doi: 10.1038/nrn2175.", "ArticleIdList": ["10.1038/nrn2175", "17643088"]}, {"Citation": "Jin F., Xie T., Huang X., Zhao X. Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Pharm. Biol. 2018;56:665\u2013671. doi: 10.1080/13880209.2018.1548627.", "ArticleIdList": ["10.1080/13880209.2018.1548627", "PMC6319470", "31070539"]}, {"Citation": "Osuka S., Van Meir E.G. Overcoming therapeutic resistance in glioblastoma: The way forward. J. Clin. Investig. 2017;127:415\u2013426. doi: 10.1172/JCI89587.", "ArticleIdList": ["10.1172/JCI89587", "PMC5272196", "28145904"]}, {"Citation": "Qu H., Song X., Song Z., Jiang X., Gao X., Bai L., Wu J., Na L., Yao Z. Berberine reduces temozolomide resistance by inducing autophagy via the ERK1/2 signaling pathway in glioblastoma. Cancer Cell Int. 2020;20:592. doi: 10.1186/s12935-020-01693-y.", "ArticleIdList": ["10.1186/s12935-020-01693-y", "PMC7727240", "33298057"]}, {"Citation": "Chai M.J., Li X., Yang H., Li H.S., Wang P., Zhao J. Effects of Berberine on Oxidative Stress and Neurological Function in Patients with Acute Ischemic Stroke. Acta Univ. Tradit. Med. Sin. Pharmacol. Shanghai. 2017;31:4. doi: 10.16306/j.1008-861x.2017.03.008.", "ArticleIdList": ["10.16306/j.1008-861x.2017.03.008"]}, {"Citation": "Chai M.J., Wang P. Effect of berberine hydrochloride on neurological function and serum malondialdehyde in patients with acute ischemic stroke. Clin. Focus. 2016;31:4. doi: 10.3969/j.issn.1004-583X.2016.10.012.", "ArticleIdList": ["10.3969/j.issn.1004-583X.2016.10.012"]}, {"Citation": "Li Y., Wang P., Chai M.J., Yang F., Li H.S., Zhao J., Wang H., Lu D.D. Effects of berberine on serum inflammatory factors and carotid atherosclerotic plaques in patients with acute cerebral ischemic stroke. Zhongguo Zhong Yao Za Zhi. 2016;41:4066\u20134071. doi: 10.4268/cjcmm20162128.", "ArticleIdList": ["10.4268/cjcmm20162128", "28929697"]}, {"Citation": "Wang X.D., Wang P.P., Zhang Y., Han Y.Z. A multicenter study effect of berberine hydrochloride on serum HIF-1\u03b1 and Caspase-3 levels in patients with acute cerebral infarction. Chin. J. Biol. Pharm. 2014;7:3."}, {"Citation": "Jia Q., Li J., Zhang J., Liu Y., Zhao Y.P., Li M.J., Li J.G. A randomized double blind study of the effect of berberine on improvement of cognitive ability in patients with schizophrenia. Chin. Ment. Health J. 2016;6:677\u2013682."}, {"Citation": "Dong W., Gu W.X., Tang X.W., Liu P., Zhao J.T., Chu X. Effect of berberine combined with risperidone therapy on endocrine hormones and oxidative stress in patients with schizophrenia. J. Hainan Med. Univ. 2017;23:4. doi: 10.13210/j.cnki.jhmu.20170809.005.", "ArticleIdList": ["10.13210/j.cnki.jhmu.20170809.005"]}, {"Citation": "Li J., Zhao Y., Liu Y., Qiu Y., Li M., Jia Q., Zhang J., Li J. The impact of berberine on insulin resistance and cytokines in patients with schizophrenia. Tianjin Med. J. 2016;44:4. doi: 10.11958/20160027.", "ArticleIdList": ["10.11958/20160027"]}, {"Citation": "Penninx B.W., Lange S.M. Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. Dialogues Clin. Neurosci. 2018;20:63\u201373.", "ArticleIdList": ["PMC6016046", "29946213"]}, {"Citation": "Qiu Y., Li M., Zhang Y., Liu Y., Zhao Y., Zhang J., Jia Q., Li J. Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian J. Psychiatry. 2021;67:102896. doi: 10.1016/j.ajp.2021.102896.", "ArticleIdList": ["10.1016/j.ajp.2021.102896", "34773803"]}, {"Citation": "Li M., Liu Y., Qiu Y., Zhang J., Zhang Y., Zhao Y., Jia Q., Li J. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2021;300:113899. doi: 10.1016/j.psychres.2021.113899.", "ArticleIdList": ["10.1016/j.psychres.2021.113899", "33812218"]}, {"Citation": "Smith S.W., Hauben M., Aronson J.K. Paradoxical and bidirectional drug effects. Drug Saf. 2012;35:173\u2013189. doi: 10.2165/11597710-000000000-00000.", "ArticleIdList": ["10.2165/11597710-000000000-00000", "22272687"]}, {"Citation": "Fu W.R., Chen J.L., Li X.Y., Dong J.X., Liu Y. Bidirectional Regulatory Mechanisms of Jaceosidin on Mitochondria Function: Protective Effects of the Permeability Transition and Damage of Membrane Functions. J. Membr. Biol. 2020;253:25\u201335. doi: 10.1007/s00232-019-00102-4.", "ArticleIdList": ["10.1007/s00232-019-00102-4", "31712855"]}, {"Citation": "Mbese Z., Khwaza V., Aderibigbe B.A. Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers. Molecules. 2019;24:4386. doi: 10.3390/molecules24234386.", "ArticleIdList": ["10.3390/molecules24234386", "PMC6930580", "31801262"]}, {"Citation": "Zhang P., Fang J., Zhang J., Ding S., Gan D. Curcumin Inhibited Podocyte Cell Apoptosis and Accelerated Cell Autophagy in Diabetic Nephropathy via Regulating Beclin1/UVRAG/Bcl2. Diabetes Metab. Syndr. Obes. 2020;13:641\u2013652. doi: 10.2147/DMSO.S237451.", "ArticleIdList": ["10.2147/DMSO.S237451", "PMC7060797", "32184643"]}, {"Citation": "Xiao H., Xue Q., Zhang Q., Li C., Liu X., Liu J., Li H., Yang J. How Ginsenosides Trigger Apoptosis in Human Lung Adenocarcinoma Cells. Am. J. Chin. Med. 2019;47:1737\u20131754. doi: 10.1142/S0192415X19500885.", "ArticleIdList": ["10.1142/S0192415X19500885", "31795742"]}, {"Citation": "Liu M., Bai X., Yu S., Zhao W., Qiao J., Liu Y., Zhao D., Wang J., Wang S. Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells. Molecules. 2019;24:2687. doi: 10.3390/molecules24152687.", "ArticleIdList": ["10.3390/molecules24152687", "PMC6696356", "31344860"]}, {"Citation": "Yu H., Chen B., Ren Q. Baicalin relieves hypoxia-aroused H9c2 cell apoptosis by activating Nrf2/HO-1-mediated HIF1alpha/BNIP3 pathway. Artif. Cells Nanomed. Biotechnol. 2019;47:3657\u20133663. doi: 10.1080/21691401.2019.1657879.", "ArticleIdList": ["10.1080/21691401.2019.1657879", "31478766"]}, {"Citation": "Huang Q., Zhang J., Peng J., Zhang Y., Wang L., Wu J., Ye L., Fang C. Effect of baicalin on proliferation and apoptosis in pancreatic cancer cells. Am. J. Transl. Res. 2019;11:5645\u20135654.", "ArticleIdList": ["PMC6789237", "31632536"]}, {"Citation": "El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066\u20131075. doi: 10.1038/sj.cdd.4400943.", "ArticleIdList": ["10.1038/sj.cdd.4400943", "11687885"]}, {"Citation": "Gerl R., Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis. 2005;26:263\u2013270. doi: 10.1093/carcin/bgh283.", "ArticleIdList": ["10.1093/carcin/bgh283", "15375012"]}, {"Citation": "Pfeffer C.M., Singh A.T.K. Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci. 2018;19:448. doi: 10.3390/ijms19020448.", "ArticleIdList": ["10.3390/ijms19020448", "PMC5855670", "29393886"]}, {"Citation": "Woynarowska B.A., Woynarowski J.M. Preferential targeting of apoptosis in tumor versus normal cells. Biochim. Biophys. Acta. 2002;1587:309\u2013317. doi: 10.1016/S0925-4439(02)00094-7.", "ArticleIdList": ["10.1016/S0925-4439(02)00094-7", "12084473"]}, {"Citation": "Zhang W., Liu H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9\u201318. doi: 10.1038/sj.cr.7290105.", "ArticleIdList": ["10.1038/sj.cr.7290105", "11942415"]}, {"Citation": "Leszek J., Barreto G.E., Gasiorowski K., Koutsouraki E., Avila-Rodrigues M., Aliev G. Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System. CNS Neurol. Disord. Drug Targets. 2016;15:329\u2013336. doi: 10.2174/1871527315666160202125914.", "ArticleIdList": ["10.2174/1871527315666160202125914", "26831258"]}, {"Citation": "Fischer R., Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxid. Med. Cell. Longev. 2015;2015:610813. doi: 10.1155/2015/610813.", "ArticleIdList": ["10.1155/2015/610813", "PMC4365363", "25834699"]}, {"Citation": "Christofidou-Solomidou M., Muzykantov V.R. Antioxidant strategies in respiratory medicine. Treat. Respir. Med. 2006;5:47\u201378. doi: 10.2165/00151829-200605010-00004.", "ArticleIdList": ["10.2165/00151829-200605010-00004", "16409015"]}, {"Citation": "Liu T., Zhang L., Joo D., Sun S.C. NF-kappaB signaling in inflammation. Signal. Transduct. Target. Ther. 2017;2:e17023. doi: 10.1038/sigtrans.2017.23.", "ArticleIdList": ["10.1038/sigtrans.2017.23", "PMC5661633", "29158945"]}, {"Citation": "Cryan J.F., O\u2019Riordan K.J., Sandhu K., Peterson V., Dinan T.G. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19:179\u2013194. doi: 10.1016/S1474-4422(19)30356-4.", "ArticleIdList": ["10.1016/S1474-4422(19)30356-4", "31753762"]}, {"Citation": "Zhu S., Jiang Y., Xu K., Cui M., Ye W., Zhao G., Jin L., Chen X. The progress of gut microbiome research related to brain disorders. J. Neuroinflamm. 2020;17:25. doi: 10.1186/s12974-020-1705-z.", "ArticleIdList": ["10.1186/s12974-020-1705-z", "PMC6969442", "31952509"]}, {"Citation": "Wang H.X., Wang Y.P. Gut Microbiota-brain Axis. Chin. Med. J. 2016;129:2373\u20132380. doi: 10.4103/0366-6999.190667.", "ArticleIdList": ["10.4103/0366-6999.190667", "PMC5040025", "27647198"]}, {"Citation": "Barichella M., Severgnini M., Cilia R., Cassani E., Bolliri C., Caronni S., Ferri V., Cancello R., Ceccarani C., Faierman S., et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Mov. Disord. 2019;34:396\u2013405. doi: 10.1002/mds.27581.", "ArticleIdList": ["10.1002/mds.27581", "30576008"]}, {"Citation": "Stanley D., Moore R.J., Wong C.H.Y. An insight into intestinal mucosal microbiota disruption after stroke. Sci. Rep. 2018;8:568. doi: 10.1038/s41598-017-18904-8.", "ArticleIdList": ["10.1038/s41598-017-18904-8", "PMC5766598", "29330443"]}, {"Citation": "Vogt N.M., Kerby R.L., Dill-McFarland K.A., Harding S.J., Merluzzi A.P., Johnson S.C., Carlsson C.M., Asthana S., Zetterberg H., Blennow K., et al. Gut microbiome alterations in Alzheimer\u2019s disease. Sci. Rep. 2017;7:13537. doi: 10.1038/s41598-017-13601-y.", "ArticleIdList": ["10.1038/s41598-017-13601-y", "PMC5648830", "29051531"]}, {"Citation": "Collins S.M., Surette M., Bercik P. The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol. 2012;10:735\u2013742. doi: 10.1038/nrmicro2876.", "ArticleIdList": ["10.1038/nrmicro2876", "23000955"]}, {"Citation": "Yano J.M., Yu K., Donaldson G.P., Shastri G.G., Ann P., Ma L., Nagler C.R., Ismagilov R.F., Mazmanian S.K., Hsiao E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264\u2013276. doi: 10.1016/j.cell.2015.02.047.", "ArticleIdList": ["10.1016/j.cell.2015.02.047", "PMC4393509", "25860609"]}, {"Citation": "Cenit M.C., Sanz Y., Codoner-Franch P. Influence of gut microbiota on neuropsychiatric disorders. World J. Gastroenterol. 2017;23:5486\u20135498. doi: 10.3748/wjg.v23.i30.5486.", "ArticleIdList": ["10.3748/wjg.v23.i30.5486", "PMC5558112", "28852308"]}, {"Citation": "Dalile B., Van Oudenhove L., Vervliet B., Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 2019;16:461\u2013478. doi: 10.1038/s41575-019-0157-3.", "ArticleIdList": ["10.1038/s41575-019-0157-3", "31123355"]}, {"Citation": "Ambrosini Y.M., Borcherding D., Kanthasamy A., Kim H.J., Willette A.A., Jergens A., Allenspach K., Mochel J.P. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. Front. Aging Neurosci. 2019;11:130. doi: 10.3389/fnagi.2019.00130.", "ArticleIdList": ["10.3389/fnagi.2019.00130", "PMC6591269", "31275138"]}, {"Citation": "Grochowska M., Laskus T., Radkowski M. Gut Microbiota in Neurological Disorders. Arch. Immunol. Ther. Exp. 2019;67:375\u2013383. doi: 10.1007/s00005-019-00561-6.", "ArticleIdList": ["10.1007/s00005-019-00561-6", "PMC6805802", "31578596"]}, {"Citation": "Stefano G.B., Pilonis N., Ptacek R., Raboch J., Vnukova M., Kream R.M. Gut, Microbiome, and Brain Regulatory Axis: Relevance to Neurodegenerative and Psychiatric Disorders. Cell Mol. Neurobiol. 2018;38:1197\u20131206. doi: 10.1007/s10571-018-0589-2.", "ArticleIdList": ["10.1007/s10571-018-0589-2", "PMC6061125", "29802603"]}, {"Citation": "Guo Y., Chen Y., Tan Z.R., Klaassen C.D., Zhou H.H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur. J. Clin. Pharmacol. 2012;68:213\u2013217. doi: 10.1007/s00228-011-1108-2.", "ArticleIdList": ["10.1007/s00228-011-1108-2", "PMC4898966", "21870106"]}, {"Citation": "Yin J., Xing H., Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712\u2013717. doi: 10.1016/j.metabol.2008.01.013.", "ArticleIdList": ["10.1016/j.metabol.2008.01.013", "PMC2410097", "18442638"]}, {"Citation": "Shou J.W., Cheung C.K., Gao J., Shi W.W., Shaw P.C. Berberine Protects C17.2 Neural Stem Cells from Oxidative Damage Followed by Inducing Neuronal Differentiation. Front. Cell. Neurosci. 2019;13:395. doi: 10.3389/fncel.2019.00395.", "ArticleIdList": ["10.3389/fncel.2019.00395", "PMC6733922", "31551713"]}, {"Citation": "Lee M.Y., Lee Y.J., Kim Y.H., Lee S.H., Park J.H., Kim M.O., Suh H.N., Ryu J.M., Yun S.P., Jang M.W., et al. Role of Peroxisome Proliferator-Activated Receptor (PPAR)delta in Embryonic Stem Cell Proliferation. Int. J. Stem Cells. 2009;2:28\u201334. doi: 10.15283/ijsc.2009.2.1.28.", "ArticleIdList": ["10.15283/ijsc.2009.2.1.28", "PMC4021791", "24855517"]}, {"Citation": "Wei S., Wang K., Zou X., Hu S., Xu L., Jiang S., Li J., Lu F. Comparative study on dynamic changes of berberine content in blood and brain tissue and bioavailability by nasal drug delivery and oral administration in rats. Chin. Arch. Tradit. Chin. Med. 2018;36:5. doi: 10.13193/j.issn.1673-7717.2018.05.003.", "ArticleIdList": ["10.13193/j.issn.1673-7717.2018.05.003"]}, {"Citation": "Heng X., Qi Y.Y., Qu S.Y., Ge P.Y., Yang N.Y., Guo R., Zhang Q.C., Zhu H.X. Distribution characteristics of nine main components of Huanglian Jiedu Decoction in rat brain. Chin. Tradit. Herb Drugs. 2020;51:8. doi: 10.7501/j.issn.0253-2670.2020.15.011.", "ArticleIdList": ["10.7501/j.issn.0253-2670.2020.15.011"]}, {"Citation": "Peng S.L.L. Effect of formula compatibility on berberine pharmacokinetics in brain tissue of rats. Chin. Tradit. Herb Drugs. 2016;47:2877\u20132882."}, {"Citation": "Ye M., Fu S., Pi R., He F. Neuropharmacological and pharmacokinetic properties of berberine: A review of recent research. J. Pharm. Pharmacol. 2009;61:831\u2013837. doi: 10.1211/jpp.61.07.0001.", "ArticleIdList": ["10.1211/jpp.61.07.0001", "19589224"]}, {"Citation": "Wang Y., Shou J.W., Li X.Y., Zhao Z.X., Fu J., He C.Y., Feng R., Ma C., Wen B.Y., Guo F., et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017;70:72\u201384. doi: 10.1016/j.metabol.2017.02.003.", "ArticleIdList": ["10.1016/j.metabol.2017.02.003", "28403947"]}, {"Citation": "Habtemariam S. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol. Res. 2020;155:104722. doi: 10.1016/j.phrs.2020.104722.", "ArticleIdList": ["10.1016/j.phrs.2020.104722", "32105754"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "1", "Day": "15"}, {"Year": "2022", "Month": "2", "Day": "21"}, {"Year": "2022", "Month": "2", "Day": "22"}, {"Year": "2022", "Month": "3", "Day": "10", "Hour": "15", "Minute": "34"}, {"Year": "2022", "Month": "3", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["35269418", "PMC8909195", "10.3390/cells11050796", "cells11050796"]}}], "PubmedBookArticle": []}